Matinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference

BEDMINSTER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative medicines using its proprietary lipid nano-crystal (“LNC”) platform delivery technology, today announced that Jerome D.  Jabbour, Chief Executive Officer of the Company, was selected to present a corporate overview and host one-on-one meetings with leading industry executives at BioNJ’s Eighth Annual BioPartnering Conference on Thursday, May 3, 2018 during the morning session being held from 10:30 a.m. – 12:30 p.m. EDT.

As part of his presentation, Mr. Jabbour will discuss the Company’s plans to use strategic collaborations to build a diverse portfolio of products leveraging its cochleate LNC drug delivery platform. Matinas’ LNC technology platform has the potential to enable safe and natural intracellular delivery of siRNAs, mRNA, proteins, DNA plasmids, small molecule pharmaceuticals and peptides. He will also discuss the advancement of its internal product candidate, MAT2203, encochleated amphotericin B, which demonstrated positive patient clinical data in 2017, as the Company is preparing for a potential Phase 2 pivotal trial for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.

BioNJ’s Eighth Annual BioPartnering Conference, developed in partnership with J.P. Morgan Chase, will bring together nearly 400 public and private company investors, life sciences professionals and academic partners from the Northeast to Mid-Atlantic states. Pharmaceutical sponsors for the conference include The Janssen Pharmaceutical Companies of Johnson & Johnson, Merck, and Pfizer. Supporting partners for this years’ conference include BIO, Bio Connecticut, Choose NJ, Delaware Bio, New Jersey Economic Development Authority, the Licensing Executives Society, MassBio, New York Bio and the Precision Medicine Leadership Summit.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative medicines using its LNC platform delivery technology. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate small molecules, oligonucleotides, vaccines and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable.

The Company's lead anti-fungal product candidate, MAT2203, positions Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.

For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP), Orphan and/or Fast Track designations for MAT2203, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

Source: Matinas BioPharma Holdings, Inc.

Released May 1, 2018